JAZZ · Jazz Pharmaceuticals PLC - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.07B | - | $1.13B | $1.05B | $897.84M | - | $1.05B | $1.02B | $901.98M | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $196.00M | - | $198.20M | $189.97M | $180.65M | - | $199.92M | $220.73M | $222.85M | - |
| SG&A | $352.70M | - | $530.65M | $358.40M | $514.01M | - | $325.77M | $338.52M | $351.71M | - |
| Total Operating Expenses | $732.30M | - | $1.07B | $1.73B | $953.73M | - | $794.76M | $824.38M | $835.78M | - |
| D&A | $9.10M | - | - | - | $10.43M | - | - | - | $7.65M | - |
| Operating Income | $336.60M | - | $57.51M | ($686.39M) | ($55.89M) | - | $260.21M | $199.44M | $66.21M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $6.10M | - | ($242.42M) | ($17.17M) | ($17.81M) | - | ($14.53M) | ($30.65M) | $11.67M | - |
| Net Income | $293.10M | - | $251.41M | ($718.47M) | ($92.54M) | - | $215.06M | $168.57M | ($14.62M) | - |
| EPS - Basic | $4.73 | - | $4.14 | ($11.74) | ($1.52) | - | $3.50 | $2.68 | ($0.23) | - |
| EPS - Diluted | $4.43 | - | $4.08 | ($11.74) | ($1.52) | - | $3.42 | $2.49 | ($0.23) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.84B | $1.39B | $1.33B | $1.19B | $1.86B | $2.41B | $2.22B | $1.36B | $1.44B | $1.51B |
| Accounts Receivable | $836.30M | $830.75M | $764.36M | $714.00M | $652.99M | $716.76M | $723.64M | $698.04M | $707.10M | $705.79M |
| Inventory | $437.50M | $416.96M | $483.11M | $504.99M | $492.78M | $480.44M | $539.30M | $542.55M | $577.32M | $597.04M |
| Accounts Payable | $100.00M | $122.06M | $152.23M | $89.37M | $95.93M | $77.87M | $85.42M | $97.10M | $80.98M | $102.75M |
| Current Assets | $4.58B | $4.17B | $3.76B | $3.35B | $4.13B | $4.63B | $4.39B | $3.68B | $3.54B | $3.44B |
| Total Assets | $11.86B | $11.66B | $11.36B | $10.94B | $11.53B | $12.01B | $12.26B | $11.36B | $11.33B | $11.39B |
| Current Liabilities | $2.25B | $2.24B | $2.27B | $2.07B | $1.22B | $1.04B | $1.03B | $1.56B | $1.56B | $1.54B |
| Long-term Debt | $4.32B | $4.33B | $4.33B | $4.34B | $5.34B | $6.08B | $6.08B | $5.10B | $5.11B | $5.11B |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | $4.53B | $4.32B | $3.96B | $3.71B | $4.17B | $4.09B | $4.17B | $3.76B | $3.70B | $3.74B |
| Retained Earnings | $939.20M | $646.18M | $442.73M | $191.31M | $1.03B | $1.13B | $936.23M | $871.18M | $864.04M | $878.66M |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $408.20M | - | - | - | $429.78M | - | - | - | $267.23M | - |
| Investing Cash Flow | $123.10M | - | - | - | ($168.93M) | - | - | - | ($271.90M) | - |
| Financing Cash Flow | ($78.50M) | - | - | - | ($813.47M) | - | - | - | ($56.55M) | - |
| CapEx | $19.70M | - | - | - | $13.88M | - | - | - | $6.90M | - |
| Free Cash Flow | $388.50M | - | - | - | $415.90M | - | - | - | $260.32M | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | 31.5% | - | 5.1% | -65.6% | -6.2% | - | 24.7% | 19.5% | 7.3% | - |
| EBITDA margin | 32.3% | - | - | - | -5.1% | - | - | - | 8.2% | - |
| Net margin | 27.4% | - | 22.3% | -68.7% | -10.3% | - | 20.4% | 16.5% | -1.6% | - |
| Free cash flow margin | 36.3% | - | - | - | 46.3% | - | - | - | 28.9% | - |
| FCF / Net income | 1.33 | - | - | - | -4.49 | - | - | - | -17.81 | - |
| R&D / Revenue | 18.3% | - | 17.6% | 18.2% | 20.1% | - | 19.0% | 21.6% | 24.7% | - |
| SG&A / Revenue | 33.0% | - | 47.1% | 34.3% | 57.2% | - | 30.9% | 33.1% | 39.0% | - |
| Effective tax rate | 2.0% | - | -2697.2% | - | - | - | -7.2% | -22.2% | - | - |
| Return on assets | 2.5% | - | 2.2% | -6.6% | -0.8% | - | 1.8% | 1.5% | -0.1% | - |
| Return on equity | 6.5% | - | 6.4% | -19.4% | -2.2% | - | 5.2% | 4.5% | -0.4% | - |
| Return on invested capital | 3.7% | - | 0.7% | -6.7% | -0.5% | - | 2.5% | 2.3% | 0.6% | - |
| Liquidity | ||||||||||
| Current ratio | 2.04 | 1.86 | 1.65 | 1.62 | 3.38 | 4.46 | 4.26 | 2.37 | 2.27 | 2.24 |
| Quick ratio | 1.85 | 1.67 | 1.44 | 1.37 | 2.97 | 3.99 | 3.74 | 2.02 | 1.90 | 1.85 |
| Cash ratio | 0.82 | 0.62 | 0.58 | 0.57 | 1.52 | 2.32 | 2.15 | 0.87 | 0.92 | 0.98 |
| Leverage | ||||||||||
| Debt / Equity | 0.95 | 1.00 | 1.09 | 1.17 | 1.28 | 1.48 | 1.46 | 1.36 | 1.38 | 1.37 |
| Debt / Assets | 0.36 | 0.37 | 0.38 | 0.40 | 0.46 | 0.51 | 0.50 | 0.45 | 0.45 | 0.45 |
| Debt / EBITDA | 12.51 | - | - | - | - | - | - | - | 69.12 | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 2.62 | 2.70 | 2.87 | 2.95 | 2.76 | 2.93 | 2.94 | 3.02 | 3.06 | 3.05 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | 0.09 | - | 0.10 | 0.10 | 0.08 | - | 0.09 | 0.09 | 0.08 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 286d | - | 248d | 249d | 265d | - | 250d | 249d | 286d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | 42.7x | - | 32.3x | - | - | - | 32.6x | 42.9x | - | - |
| P / B | 2.8x | - | 2.1x | 1.8x | 1.8x | - | 1.7x | 2.0x | 2.0x | - |
| P / S | 11.7x | - | 7.2x | 6.2x | 8.4x | - | 6.7x | 7.3x | 8.3x | - |
| EV / EBITDA | 43.3x | - | - | - | - | - | - | - | 151.5x | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 19.1% | - | 6.7% | 2.1% | -0.5% | - | 8.5% | 6.9% | 1.0% | - |
| Revenue CAGR (3y) | 6.2% | - | 6.2% | 3.9% | 3.3% | - | 8.0% | 10.8% | 14.1% | - |
| Revenue CAGR (5y) | 12.0% | - | 13.4% | 13.2% | 10.9% | - | 14.4% | 13.9% | 12.2% | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | - | -77.9% | - | - | - | 50.9% | 26.5% | -47.5% | - |
| Net income growth (YoY) | - | - | 16.9% | - | -533.1% | - | 46.5% | 61.4% | - | - |
| EPS growth (YoY) | - | - | 19.3% | - | -560.9% | - | 59.8% | 63.8% | - | - |
| EPS CAGR (3y) | 62.1% | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | 16.2% | - | 9.1% | - | - | - | 14.0% | -11.4% | - | - |
| FCF growth (YoY) | -6.6% | - | - | - | 59.8% | - | - | - | -17.8% | - |
| FCF CAGR (5y) | 6.6% | - | - | - | 9.2% | - | - | - | 6.0% | - |
| Book value growth (YoY) | 8.6% | 5.5% | -5.1% | -1.5% | 12.9% | 9.5% | 19.5% | 6.7% | 10.8% | 21.1% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$12.54B totalProduct And Services Product Sales Net Of Deductions$4.02B · 32.1%
Total Neuroscience$2.88B · 22.9%
Xywav$1.66B · 13.2%
Total Oncology$1.13B · 9.0%
Epidiolex Epidyolex$1.06B · 8.4%
Rylaze Enrylaze$402.92M · 3.2%
Zepzelca$307.31M · 2.5%
Product And Services Royalties And Contract Revenue$245.74M · 2.0%
High Sodium AGOxybate Product Royalty Revenue$211.72M · 1.7%
Defitelio Defibrotide$199.39M · 1.6%
Vyxeos$146.71M · 1.2%
Xyrem$146.03M · 1.2%
Modeyso$48.04M · 0.4%
Other Royalties And Contract Revenue$34.01M · 0.3%
Ziihera$24.81M · 0.2%
Sativex$16.28M · 0.1%
Other Products$14.17M · 0.1%
Geographic
$4.27B totalUS$3.83B · 89.8%
Europe$341.12M · 8.0%
Other Countries$94.87M · 2.2%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Jazz Pharmaceuticals plc against the 5 most active filers in the same SIC group.